Literature DB >> 21043242

Binding of psychotropic drugs to isolated alpha-acid glycoprotein.

M L Kornguth1, L G Hutchins, B S Eichelman.   

Abstract

Alpha1-acid glycoprotein (alpha1-AG) was purified from human sera, and its binding properties with respect to psychotropic drugs were examined by equilibrium dialysis methods in order to clarify the specificity of binding. Radioactive imipramine, a tricyclic antidepressant, was used as the primary ligand. Other drugs, representative of different classes, were tested as potential inhibitors of the alpha1-AG-imipramine binding. The K(a) for imipramine was 2.8 x 10(5) (+/- 0.8) M(-10 (mean +/- S.D.). Chlorpromazine, fluphenazine, thioridazine, loxapine and thiothixene, which are antipsychotic drugs, were competitive inhibitors of imipramine binding, and their K(a) values were in the same range. Propranolol, haloperidol and diazepam were also competitive inhibitors but their affinities were lower. Molindone, an indolic antipsychotic, when tested at the same concentrations as the other drugs, did not affect imipramine binding. Trihexyphenidyl, an anti-Parkinson drug, was a potent but noncompetitive inhibitor. These data identify the antidepressant and major tranquilizer drugs that exhibit high affinity for alpha1-AG and indicate that alpha1-AG may account for 40 per cent of total imipramine bound in serum. Since in psychiatric clinical practice two drugs are frequently administered together, possible competitive effects are discussed as well as the potential role of alpha1-AG in psychiatric illness.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 21043242     DOI: 10.1016/0006-2952(81)90338-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  Selectivity in the binding of psychotropic drugs to the variants of alpha-1 acid glycoprotein.

Authors:  C B Eap; C Cuendet; P Baumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-02       Impact factor: 3.000

2.  Interindividual differences in the binding of antidepressives to plasma proteins: the role of the variants of alpha 1-acid glycoprotein.

Authors:  D Tinguely; P Baumann; M Conti; M Jonzier-Perey; J Schöpf
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 3.  The significance of plasma protein binding on the fetal/maternal distribution of drugs at steady-state.

Authors:  M D Hill; F P Abramson
Journal:  Clin Pharmacokinet       Date:  1988-03       Impact factor: 6.447

Review 4.  The role of the liver in clearance of glycoproteins from the general circulation, with special reference to intestinal alkaline phosphatase.

Authors:  D K Meijer; H B Scholtens; M J Hardonk
Journal:  Pharm Weekbl Sci       Date:  1982-06-25

5.  The binding of ketamine to plasma proteins: emphasis on human plasma.

Authors:  P G Dayton; R L Stiller; D R Cook; J M Perel
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  Protein binding of anthraquinone glycosides, with special reference to adriamycin.

Authors:  S Eksborg; H Ehrsson; B Ekqvist
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

7.  Characterization of a common binding site for basic drugs on human alpha 1-acid glycoprotein (orosomucoid).

Authors:  W E Müller; A E Stillbauer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-03       Impact factor: 3.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.